Ento Llc Pharmaceutical Import Profile — South Korea (DGFT 2022–2026)

Name: Ento Llc Pharmaceutical Import Records from India — 2 Products, $400.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ento Llc — Pharmaceutical Importer Profile (2026) | 2 Products, $400.0K Trade | TransData Nexus

Ento Llc

Pharmaceutical Importer · South Korea · Antihistamines & Allergy Focus · $400.0K Total Trade · DGFT Verified

Ento Llc is a pharmaceutical importer based in South Korea with a total trade value of $400.0K across 2 products in 2 therapeutic categories. Based on 8 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Ento Llc sources from 3 verified Indian suppliers, with Brawn Laboratories Limited accounting for 81.0% of imports.

Ento Llc — Import Portfolio & Supplier Network

Ento Llc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Ento Llc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Brawn Laboratories Limited	$489.8K	16	81.0%
Procare Pharma Private Limited	$85.8K	22	14.2%
Infugen Life Sciences Private Limited	$28.8K	3	4.8%

What Formulations Does Ento Llc Import?

Formulation	Value	Ships
Each uncoated tablet conts.	$100.0K	2
Each film coated tablet conts	$50.0K	1
Each uncoated tablet conts. montelucastsodium BP eq. to montelucast 10MG & levocetirizine dihyrochloride USP	$50.0K	1
Each uncoated tablets conts. colchicinebp 0.5MG(excipients qs)(cocilone-0.5)b.no.bnt1023031,d/m:10/23	$50.0K	1
(mastic lc)Each uncoated tablet conts. montelukast sodium BP eq.to montelukast 10MG levocetirizine dihydrochloride USP	$50.0K	1
(mastic lc)Each uncoated tablet conts. montelucast sodium BP eq. to montelucast10mg & levocetirizine dihyrochloride	$50.0K	1
(mastic lc)Each uncoated tablet conts.montelucast sodium BP e.q. to montelucast10mg & levocetirizine dihydrochloride	$50.0K	1
Pharmaceutical drugs & medicines- Each	$23.3K	1
Azibru 500 Each film coated tablets conts. azithromycin anhydrous 500MG (as azithromycin dihydrate USP b.no.bnt1123036	$22.4K	1
Harmless medicines-doripenem for injection 500MG, clear glass vial 10ML n1, b/ no dn-2401 mfg: jan 2024 , exp. dec	$14.2K	1
Pharmaceutical products: soranib	$13.2K	1
Soranib 200MG (sorafenib tablets IP	$12.3K	1
Harmless medicines doripenem for injection 1000MG clear glass vial 20ML n1 b no dn 2302 mfg feb 2023 exp jan	$10.8K	2
Harmless medicines-doripenem for	$10.5K	2
Harmless medicines doripenem for injection 500MG clear glass vial 10ML n1 b no dn 2301 mfg feb 2023 exp jan	$10.2K	2

Ento Llc imports 33 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Cetirizine	Antihistamines & Allergy	$200.0K	4	0.1%	10
2	Colchicine	Lipid & Metabolism	$200.0K	4	0.9%	5

Ento Llc imports 2 pharmaceutical products across 2 categories into South Korea totaling $400.0K.

Ento Llc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Ento Llc is a pharmaceutical importer based in South Korea, specializing in the acquisition of finished pharmaceutical formulations from international suppliers. The company plays a pivotal role in the South Korean pharmaceutical distribution network, ensuring the availability of essential medications to meet domestic healthcare needs. While specific details about its parent company and exact headquarters location are not publicly disclosed, Ento Llc's operations are integral to the country's pharmaceutical supply chain.

2Distribution Network

Ento Llc's distribution network encompasses strategically located warehouses across South Korea, facilitating efficient storage and distribution of imported pharmaceutical products. The company's logistics capabilities are designed to ensure timely delivery to various regions within the country, thereby supporting the prompt availability of medications to healthcare providers and patients. While the company primarily focuses on the South Korean market, its sourcing operations extend beyond national borders, reflecting a global approach to procurement.

3Industry Role

In South Korea's pharmaceutical supply chain, Ento Llc functions as a primary wholesaler and importer. By sourcing finished pharmaceutical formulations from international suppliers, the company bridges the gap between global manufacturers and the domestic market, ensuring that a diverse range of medications is accessible to meet the healthcare needs of the population. This role is crucial in maintaining the stability and reliability of the pharmaceutical supply chain within the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Ento Llc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Ento Llc's sourcing strategy exhibits a high degree of concentration, with a total import value of $400,000 USD from India across 8 shipments, focusing on two primary products: Cetirizine and Colchicine. This concentrated sourcing approach suggests a strategic choice to leverage specific suppliers for these products, potentially benefiting from established relationships and favorable terms. However, the limited number of suppliers and products may expose the company to risks associated with supply chain disruptions or changes in supplier dynamics. The shipment data indicates a stable relationship with the current suppliers, as evidenced by the consistent import volumes over the period.

2Supply Chain Resilience

The resilience of Ento Llc's Indian supply chain appears robust, given the consistent import volumes and the established relationships with suppliers such as Brawn Laboratories Limited, Procare Pharma Private Limited, and Infugen Life Sciences Private Limited. The diversity in formulations—33 unique formulations—indicates a level of flexibility in sourcing. However, the company's reliance on a limited number of suppliers and products could pose challenges in the event of supply chain disruptions. Ensuring compliance with Good Manufacturing Practices (GMP) and maintaining alternative supplier options are essential strategies to enhance supply chain resilience.

Importing Pharmaceuticals into South Korea — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for South Korea

1Regulatory Authority & Framework

The Ministry of Food and Drug Safety (MFDS) is the primary regulatory authority overseeing the pharmaceutical sector in South Korea. The MFDS is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products through stringent regulations and oversight. Key legislation governing pharmaceutical imports includes the Pharmaceutical Affairs Act, which outlines the requirements for drug approval, importation, and distribution. The approval process involves a comprehensive evaluation of safety and efficacy data, manufacturing practices, and labeling compliance. (khidi.or.kr)

2Import Licensing & GMP

Importers of pharmaceutical products into South Korea must obtain an Import Drug License from the MFDS, demonstrating compliance with regulatory standards. Additionally, imported pharmaceuticals must adhere to Good Manufacturing Practice (GMP) standards, ensuring product quality and safety. GMP certification is mandatory for all pharmaceutical products entering South Korea, and the MFDS conducts inspections to verify compliance.

3Quality & Labeling

Ento Llc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Ento Llc's focus on importing Cetirizine and Colchicine aligns with the therapeutic needs of the South Korean market, particularly in the areas of antihistamines and lipid metabolism disorders. The demand for these products is driven by the prevalence of allergic conditions and metabolic disorders among the population. By concentrating on these therapeutic areas, Ento Llc addresses significant healthcare needs, ensuring the availability of essential medications to the public.

2Sourcing Profile

Ento Llc's sourcing strategy emphasizes the procurement of generic drugs, primarily focusing on formulations that are well-established and widely used in the treatment of allergies and metabolic disorders. The company's preference for finished pharmaceutical formulations indicates a strategic approach to ensure product quality and regulatory compliance. India's robust pharmaceutical manufacturing capabilities and adherence to international standards make it a suitable partner for Ento Llc's procurement needs.

3Market Positioning

Based on its product mix, Ento Llc serves the wholesale distribution segment of the South Korean pharmaceutical market. By importing and distributing essential medications, the company ensures that retail pharmacies, hospitals, and healthcare providers have access to necessary treatments, thereby supporting the overall healthcare infrastructure in the country.

Seller's Guide — How to Become a Supplier to Ento Llc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Ento Llc, particularly by offering a diverse range of formulations that meet South Korean regulatory standards. Gaps in Ento Llc's current sourcing include a limited number of suppliers and products, which presents an opportunity for Indian exporters to introduce additional products and suppliers to diversify the supply chain. Ensuring compliance with GMP and MFDS regulations will be crucial for establishing successful partnerships.

2Requirements & Qualifications

Indian exporters seeking to supply Ento Llc and the South Korean market must obtain GMP certification recognized by the MFDS. Additionally, they must ensure that their products comply with South Korean labeling requirements, including Korean-language labels and serialization mandates. Importers must also obtain an Import Drug License from the MFDS, demonstrating adherence to regulatory standards.

3How to Approach

To build a relationship with Ento Llc, Indian exporters should initiate contact to understand the company's specific product requirements and regulatory expectations. Participating in tenders and responding to requests for proposals can provide opportunities to showcase product offerings. Developing a comprehensive regulatory filing strategy that aligns with MFDS requirements and establishing a clear timeline for product registration and approval will be essential steps in the process.

Frequently Asked Questions — Ento Llc

What products does Ento Llc import from India?

Ento Llc imports 2 pharmaceutical products across 2 categories. Top imports: Cetirizine ($200.0K), Colchicine ($200.0K).

Who supplies pharmaceuticals to Ento Llc from India?

Ento Llc sources from 3 verified Indian suppliers. The primary supplier is Brawn Laboratories Limited (81.0% of imports, $489.8K).

What is Ento Llc's total pharmaceutical import value?

Ento Llc's total pharmaceutical import value from India is $400.0K, based on 8 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Ento Llc focus on?

Ento Llc imports across 2 categories. The largest: Antihistamines & Allergy (50.0%), Lipid & Metabolism (50.0%).

Get Full Ento Llc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.